Xilin Wu

Xilin Wu

Auto-generated profile, based on publicly available information

Xilin Wu

Endocrine Hypertension, Department of Clinical Pharmacology and Precision Medicine, William Harvey Research Institute, Queen Mary University of London, United Kingdom (M.J.B., X.W.).

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
XWXilin Wu
Xilin Wu
RSRussell Senanayake
Russell Senanayake
EGEmily Goodchild
Emily Goodchild
WBWaiel A. Bashari
Waiel A. Bashari
JSJackie Salsbury
Jackie Salsbury
MBMorris J. Brown
Morris J. Brown
Primary aldosteronism (PA) due to a unilateral aldosterone-producing adenoma is a common cause of hypertension. This can be cured, or greatly improved, by adrenal surgery. However, the invasive nature of the standard pre-surgical investigation contributes to fewer than 1% of patients with PA being offered the chance of a cure. The primary objective of our prospective study of 143 patients with PA (NCT02945904) was to compare the accuracy of a non-invasive test, [11C]metomidate positron emission tomography computed tomography (MTO) scanning, with adrenal vein sampling (AVS) in predicting the biochemical remission of PA and the resolution of hypertension after surgery. A total of 128 patients reached 6- to 9-month follow-up, with 78 (61%) treated surgically and 50 (39%) managed medically. Of the 78 patients receiving surgery, 77 achieved one or more PA surgical outcome criterion for success. The accuracies of MTO at predicting biochemical and clinical success following adrenalectomy were, respectively, 72.7 and 65.4%. For AVS, the accuracies were 63.6 and 61.5%. MTO was not significantly superior, but the differences of 9.1% (95% confidence interval = −6.5 to 24.1%) and 3.8% (95% confidence interval = −11.9 to 9.4) lay within the pre-specified −17% margin for non-inferiority (P = 0.00055 and P = 0.0077, respectively). Of 24 serious adverse events, none was considered related to either investigation and 22 were fully resolved. MTO enables non-invasive diagnosis of unilateral PA.

3 July 2019 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
DMDongwen Ma
Dongwen Ma
TXTong Xu
Tong Xu
GCGuoqiang Cai
Guoqiang Cai
XWXilin Wu
Xilin Wu
ZLZhendong Lei
Zhendong Lei
NYNing Yang
Ning Yang
Effects of ivabradine hydrochloride (Iva) and trimetazidine on myocardial fibrosis (MF) in rats with chronic heart failure (CHF) werφe explored. Fifty Wistar rats were randomly divided into sham operation, model, Iva, trimetazidine and combined drug group with 10 rats each. All rats except those in sham operation group were subjected to establish CHF model by constricting the abdominal aorta. After successful modeling, rats in the sham operation and model group received normal saline (10 mg/kg) gavage daily, the Iva group received Iva (10 mg/kg) gavage, the trimetazidine group received trimetazidine (10 mg/kg) gavage, and the combined drug group were given Iva (10 mg/kg) and trimetazidine (10 mg/kg) gavage for 12 weeks. The changes of hemodynamic indexes and heart rate, connective tissue growth factor (CTGF) and superoxide dismutase (SOD) levels as well as transforming growth factor β1 (TGF-β1) and collagen I (COL-I) expression levels in myocardial tissue of each group were detected. Compared with sham operation group, the left ventricular end-diastolic pressure (LVEDP) level, CTGF expression, TGF-β1 mRNA and COL-I mRNA expression levels in model group increased significantly, but the ± dp/dtmax and SOD content in myocardial tissue decreased significantly. Compared with model group, the LVEDP level, CTGF expression, TGF-β1 mRNA and COL-I mRNA expression levels in Iva group, trimetazidine group and combined drugs decreased significantly, but the ± dp/dtmax and the SOD content in myocardial tissue increased significantly (P<0.05). Changes in the combined drug group were the most notable (P<0.05). Iva combined with trimetazidine reduces LVEDP in rat with CHF, increases SOD content, and inhibits CTGF expression and TGF-β1 and COL-I expression levels in myocardial tissues, thus achieving the inhibitory effect on MF.

10 October 2017 in Future Oncology
Verified
Journal Article
Closed access
JCJianxin Chen
Jianxin Chen
JWJunhui Wang
Junhui Wang
XWXilin Wu
Xilin Wu
XCXiaoling Che
Xiaoling Che
AZAnne (Yan) Zou
Anne (Yan) Zou
QZQinhong Zheng
Qinhong Zheng
Aim: We performed a meta-analysis to evaluate the efficacy and safety for S-1-based regimens as the first-line treatment in Asian chemotherapy-naive patients with advanced non-small-cell lung cancer. Patients & methods: Eligible randomized clinical trials (RCTs) were included, of which data were extracted by inclusion criteria and exclusion one. Odds ratio and hazard ratio (HR) of outcomes including objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse effects (AEs) were explored for the final analysis. Results: Twenty-one RCTs including 3263 patients were fit into the analysis. Pooled HR for PFS was 1.01 (95% CI: 0.92–1.10; p = 0.88), the pooled HR for OS was 0.95 (95% CI: 0.85–1.06; p = 0.33) and the pooled odds ratio for ORR was 0.74 (95% CI: 0.61–0.90; p = 0.003). S-1-based regimens showed milder AEs in high-grade nausea/vomit, anorexia, leukopenia, neutropenia and febrile neutropenia (all p < 0.05). Conclusion: The present study has revealed that S-1-based ...

29 November 2022 in Medical Science Monitor
Verified
Journal Article
Open access
XWXilin Wu
Xilin Wu
SZShiming Zhang
Shiming Zhang
YJYingzhu Jin
Yingzhu Jin
XXXun Xiao
Xun Xiao
At present, whether sitagliptin has sex-related differences in effect on atherosclerosis in type 2 diabetes mellitus (T2DM) patients is unknown. The purpose of this study was to investigate whether there is sex-related difference in the effect of sitagliptin on atherosclerosis in T2DM patients. In the PROLOGUE trial, 222 patients were allocated to the sitagliptin group and 220 patients were allocated to the conventional group. Carotid artery intima-media thickness (IMT) was assessed at baseline, 12 months, and 24 months. In male patients, sitagliptin significantly reduced the mean IMT (0.84±0.41 mm vs 1.02±0.67 mm, P=0.013) and the maximum IMT (1.14±0.59 mm vs 1.39±0.88 mm, P=0.016) in the right internal carotid arteries (ICA) compared to the conventional group at 12 months. Similarly, sitagliptin significantly reduced the maximum IMT (1.09±0.52 mm vs 1.28±0.77 mm, P=0.049) in the right ICA compared to the conventional group at 24 months, but no difference was found in the mean IMT in the right ICA between groups at 24 months. In female patients, sitagliptin significantly reduced the mean IMT (1.01±0.47 mm vs 1.23±0.51 mm, P=0.049) and the maximum IMT (1.39±0.65 mm vs 1.71±0.77 mm, P=0.042) in the right bulb compared to the conventional group at 12 months. However, the group differences were not observed in mean IMT and maximum IMT at 24 months. Our results suggest that sitagliptin slows the progression of right carotid IMT in male patients. However, more research is needed to validate this finding in female patients.

1 June 2025 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
PDF file
XWXilin Wu
Xilin Wu
AMAlasdair McIntosh
Alasdair McIntosh
AMAlex McConnachie
Alex McConnachie
MGMark Gurnell
Mark Gurnell
WDWilliam M Drake
William M Drake
MBMorris J Brown
Morris J Brown
Background: Primary aldosteronism due to a unilateral aldosterone-producing adenoma is a common cause of hypertension. This can be cured or greatly improved by adrenal surgery. However, the invasive nature of the standard presurgical investigation contributes to fewer than 1% of patients with primary aldosteronism being offered the chance of a cure. Objectives: The primary objective of our prospective study was to compare the accuracy of a non-invasive test, [11C]metomidate positron emission tomography computed tomography scanning, with adrenal vein sampling in predicting the biochemical remission of primary aldosteronism and the resolution of hypertension after surgery. Design and methods: All participants of the study underwent both investigations, in random order, as determined by minimisation. Individuals were recommended for surgery if one or both investigations indicated unilateral primary aldosteronism. Biochemical and clinical outcomes were assessed at 6 months post surgery, or after 9–12 months of medical therapy. In November 2019, the MATCH extension study was added to address two study limitations. Firstly, the short (20-minute) half-life of [11C]-metomidate, which currently limits its use to centres with an on-site cyclotron. Secondly, the short, 6-month interval between surgery and primary outcome determination. Development of para-chloro-2-[18F]fluoroethyletomidate, an 18F analogue of [11C]-metomidate with a 109-minute half-life, allowed an within-patient comparison of para-chloro-2-[18F]fluoroethyletomidate and [11C]metomidate positron emission tomography in 31 participants in the extension study. The extension also allowed assessment of outcomes at 2 years post intervention. Results: In the original MATCH study, a total of 128 patients reached 6- to 9-month follow-up, with 78 (61%) treated surgically and 50 (39%) managed medically. The accuracies of [11C]metomidate positron emission tomography and computed tomography at predicting biochemical and clinical success following adrenalectomy were, respectively, 72.7% and 65.4%. For adrenal vein sampling, the accuracies were 63.6% and 61.5%. [11C]metomidate positron emission tomography and computed tomography was not significantly superior, but the differences of 9.1% (95% confidence interval −6.5% to 24.1%) and 3.8% (95% confidence interval −11.9% to 9.4%) lay within the pre-specified−17% margin for non-inferiority (p = 0.00055 and p = 0.0077, respectively). At 2 years post surgery, partial/complete or complete clinical success were achieved in 78/96 (81%) and 24/96 (25%) of patients, respectively. Comparing patients whose systolic blood pressure was ≤ 135 or > 135 mmHg on spironolactone, complete clinical success occurred in 9/19 and 6/44, respectively (odds ratio 5.7, 95% confidence interval 1.6 to 19.8; p = 0.008); 10/14 (71%) patients harbouring KCNJ5 mutations achieved complete clinical success at 2 years (odds ratio 16.9, 95% confidence interval 3.5 to 80.7; p = 0.0002), compared with 0/16 with CACNA1D and 4/15 with other mutations. There was high agreement in prediction of unilateral primary aldosteronism: [11C]metomidate positron emission tomography and computed tomography 18/31 (58.1%), para-chloro-2-[18F]fluoroethyletomidate 17/31 (54.8%), κ = 0.850, 95% confidence interval (0.676 to 1.000). Limitations: Accuracy of [11C]metomidate positron emission tomography and computed tomography and adrenal vein sampling could only be assessed in the surgical group. The assumption was made that if both investigations indicated bilateral disease, this was accurate; which is a limitation of the study. Furthermore, the accuracy of para-chloro-2-[18F]fluoroethyletomidate was assessed against [11C]metomidate positron emission tomography, which we know from the overall study is not perfect as a small proportion of aldosterone-producing adenomas were diagnosed by only one investigation. Further work is required to ascertain reasons for this discrepancy. Conclusions: Overall, [11C]metomidate positron emission tomography is non-inferior to adrenal vein sampling in detecting unilateral primary aldosteronism. Favourable clinical Primary Aldosteronism Surgical Outcome study outcomes seen at 6 months post adrenalectomy are sustained at 2 years and are predicted by genotype and preoperative response to spironolactone. Para-chloro-2-[18F]fluoroethyletomidate is a valid alternative to [11C]metomidate positron emission tomography in primary aldosteronism subtyping. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme as award number 14/145/09.

1 September 2026 in Hypertension
Verified
Journal Article
Closed access
JYJun Yang
Jun Yang
JGJessica Goi
Jessica Goi
Jacopo BurrelloJacopo Burrello
Jacopo Burrello
MPMartin Reincke Prof
Martin Reincke Prof
CAChristian Adolf
Christian Adolf
PFPeter J. Fuller
Peter J. Fuller
BACKGROUND: Primary aldosteronism (PA) is a common and treatable cause of hypertension, yet data on the durability of medical treatment response beyond the first year are limited. Using the PA medical treatment outcomes framework, we evaluated long-term biochemical and clinical outcomes and factors associated with treatment response. METHODS: We conducted an international, multicenter, observational cohort study across 27 centers on 4 continents. Adults with PA treated with mineralocorticoid receptor antagonists and/or epithelial sodium channel blockers between 2016 and 2021 were included if follow-up data were available at ≥12 months. Biochemical and clinical responses were classified as complete, partial, or absent using PA medical treatment outcomes criteria. Ordinal logistic regression identified determinants of a favorable treatment response. RESULTS: The cohort included 1292 patients (47.5% women, mean age 52 years) with a median follow-up of 34 months (interquartile range, 21–51). At ≥12 months, 58.3% achieved a complete biochemical response, and 20.8% achieved a complete clinical response, with only 5% showing no response. Determinants of a favorable biochemical response included lower aldosterone and lateralization index, and higher renin and potassium levels at baseline. In those taking spironolactone, a higher daily dose was also associated with a favorable biochemical response. Determinants of a favorable clinical response included female sex, lower body mass index, shorter duration of hypertension, and absence of hypertension-mediated organ damage. CONCLUSIONS: Targeted medical therapy for PA can deliver sustained biochemical and clinical benefits. Early disease detection and adequate dose titration are highly actionable determinants of long-term treatment success.